BTG PLC (BTG.L)

BTG.L on London Stock Exchange

735.50GBp
20 Apr 2015
Change (% chg)

-11.50p (-1.54%)
Prev Close
747.00p
Open
750.50p
Day's High
753.00p
Day's Low
733.00p
Volume
1,599,045
Avg. Vol
653,678
52-wk High
835.87p
52-wk Low
508.50p

BTG.L

Chart for BTG.L

About

BTG plc is a United Kingdom-based specialist healthcare company focused on developing and commercializing products targeting acute care, cancer and vascular diseases. The Company operates in three business segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. Its Interventional Medicines include Interventio... (more)

Overall

Beta: 0.40
Market Cap(Mil.): £2,851.87
Shares Outstanding(Mil.): 381.78
Dividend: --
Yield (%): --

Financials

  BTG.L Industry Sector
P/E (TTM): 68.69 40.59 41.17
EPS (TTM): 0.11 -- --
ROI: 6.13 16.74 16.08
ROE: 7.14 17.27 16.92
Search Stocks

British drugs firm BTG lifts 2014/15 sales forecast

LONDON, April 2 - British drugs company BTG nudged up its 2014/15 revenue forecast on Thursday and said it was on course for further strong growth in its new financial year.

02 Apr 2015

BRIEF-Britihs pharma co BTG launches ADR programme

* Adr programme will be open for deposits from 9 a.m. (est) today Source text for Eikon: Further company coverage:

19 Feb 2015

British drugs company BTG lifts revenue guidance

LONDON, Feb 5 - British drugs company BTG lifted its forecast for annual revenues by as much as 4 percent on Thursday, citing the benefits of a U.S. acquisition and the reversal of currency headwinds.

05 Feb 2015

BRIEF-BTG raises full-year revenue forecast

* Full year revenue is now expected to be in range 345 mln-360 mln stg; previous guidance was 330 mln-345 mln stg

05 Feb 2015

BRIEF-BTG raises about 150 mln stg by placing new shares

* Placing raised proceeds of approximately 150 mln stg (before expenses)

04 Dec 2014

CORRECTED-BRIEF-BTG to acquire Pneumrx for up to $475 mln, funded by placing

* Announce that it has entered into an agreement to acquire pneumrx inc on a debt free cash free basis for an initial cash consideration of us$230 million

04 Dec 2014

BTG to buy lung intervention firm for up to $475 mln

LONDON, Dec 4 - BTG, the healthcare group best known for treating rattlesnake bites and varicose veins, is expanding into lung care by buying a Californian firm that has developed a device to prop open airways.

04 Dec 2014

BTG says long-awaited varicose vein treatment has positive debut

Nov 11 - British drugs company BTG said it had started to roll out its varicose vein treatment to a positive response in the United States, as it said revenue for the year would be at the top end of forecasts.

11 Nov 2014

BRIEF-BTG posts rise in H1 profit, sees full-year revenue at top end

* Operating profit increased to £42.8m (h1 13/14: £25.0m)

11 Nov 2014

Earnings vs. Estimates

Search Stocks